[go: up one dir, main page]

US20090186908A1 - Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy - Google Patents

Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy Download PDF

Info

Publication number
US20090186908A1
US20090186908A1 US12/222,534 US22253408A US2009186908A1 US 20090186908 A1 US20090186908 A1 US 20090186908A1 US 22253408 A US22253408 A US 22253408A US 2009186908 A1 US2009186908 A1 US 2009186908A1
Authority
US
United States
Prior art keywords
agent
diabetic neuropathy
treatment
inhibitor
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/222,534
Inventor
Norman E. Cameron
Mary A. Cotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Individual filed Critical Individual
Priority to US12/222,534 priority Critical patent/US20090186908A1/en
Publication of US20090186908A1 publication Critical patent/US20090186908A1/en
Priority to US13/048,377 priority patent/US20120041010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
  • ARI aldose reductase inhibitor
  • ACE angiotensin converting enzyme
  • AII angiotensin II
  • HMG Co A reductase inhibitors effectively inhibit cholesterol synthesis in the liver through stimulation of the low density lipoprotein (LDL) receptors.
  • LDL low density lipoprotein
  • HMG Co A reductase inhibitors are currently pre-eminent in the treatment of all hypercholesterolaemia, except the relatively rarely occurring homozygous familial hypercholesterolaemia.
  • Therapy with HMG Co A-reductase inhibitors may result in regression of atherosclerotic vascular lesions and several HMG Co A-reductase inhibitors have proven to reduce mortality.
  • Various HMG Co A-reductase inhibitors are marketed, and are collectively referred to as ‘statins’.
  • statin drugs in particular (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the AGENT), the calcium salt of which is shown in FIG. 1 below, and atorvastatin produce an improvement in the nerve conduction velocity (NCV) and nerve blood flow in an animal model of diabetic neuropathy. Therefore, statin drugs may be used to improve diabetic neuropathy, whether in type I or type II diabetes.
  • NCV nerve conduction velocity
  • a method for treating neuropathy in a patient suffering from diabetes comprising administering to the patient a statin drug.
  • a method for improving nerve conduction velocity and/or nerve blood flow in a patient suffering diabetic neuropathy comprising administering to the patient a statin drug.
  • statin drug in the preparation of a medicament for use in the treatment of any of the conditions mentioned above.
  • statin drugs include, for example, pravastatin (PRAVACHOLTM, lovastatin (MEVACORTM), simvastatin (ZOCORTM), cerivastatin (LIPOBAYTM), fluvastatin (LESCOLTM), atorvastatin (LIPITORTM) and the AGENT, the structures of which are shown in FIG. 1.
  • the statin drug is atorvastatin or the AGENT.
  • the AGENT is used at a dose of 5 to 80 mg per day.
  • the AGENT is disclosed in European Patent Application, Publication No. 0521471, and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444 as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase).
  • HMG-CoA reductase 3-hydroxy-3-methylglutaryl CoA reductase
  • the calcium salt is used as illustrated in FIG. 1.
  • Atorvastatin is disclosed in U.S. Pat. No. 5,273,995; lovastatin is disclosed in U.S. Pat. No. 4,231,938; simvastatin is disclosed U.S. Pat. No. 4,450,171 and U.S. Pat. No. 4,346,227; pravastatin is disclosed in U.S. Pat. No. 4,346,227; fluvastatin is disclosed in U.S. Pat. No. 4,739,073; cerivastatin is disclosed in U.S. Pat. No. 5,177,080 and U.S. Pat. No. 5,006,530.
  • statin drug may be administered in accordance with the invention in combination with other drugs used for treating diabetes or the complications of diabetes, such as neuropathy, nephropathy, retinopathy and cataracts.
  • drugs used for treating diabetes such as neuropathy, nephropathy, retinopathy and cataracts.
  • examples of such treatments include insulin sensitising agents, insulin and oral hypoglycaemics (these are divided into four classes of drug—sulfonylureas, biguanides, prandial glucose regulators and alpha-glucosidase inhibitors).
  • insulin sensitising agents include, for example, troglitazone, rosiglitazone, pioglitazone, MCC-555, (S)-2-ethoxy-3-[4-(2- ⁇ 4-methanesulfonyloxyphenyl ⁇ ethoxy)phenyl]propanoic acid and 3- ⁇ 4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl ⁇ -(S)-2-ethoxy propanoic acid.
  • sulfonylureas are glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide.
  • An example of a biguanide is metformin.
  • An example of an alpha-glucosidase inhibitor is acarbose.
  • An example of a prandial glucose regulator is repaglinide.
  • aldose reductase inhibitors or ACE inhibitors in improving NCV and treating diabetic neuropathy is disclosed in PCT/GB98/01959.
  • AII antagonists in improving NCV and treating diabetic neuropathy is disclosed in WO93/20816.
  • Suitable aldose reductase inhibitors include, for example, epalrestat, tolrestat, ponolrestat, zopolrestat, AD-5467, SNK-860, ADN-138, AS-3201, zenarestat, sorbinil, methosorbinil, imirestat and minalrestat (WAY-121509).
  • Suitable ACE inhibitors include, for example, benazepril, benazeprilat, captopril, delapril, fentiapril, fosinopril, imidopril, libenzapril, moexipril, pentopril, perindopril, pivopril, quinapril, quinaprilat, ramipril, spirapril, spiraprilat, trandolapril, zofenopril, ceronapril, enalapril, indolapril, lisinopril, alacepril, and cilazapril.
  • a preferred ACE inhibitor includes, for example, lisinopril, or a pharmaceutically acceptable salt thereof.
  • Suitable AII antagonists include, for example, losartan, irbesartan, valsartan and candesartan.
  • a preferred AII antagonist is candesartan.
  • independent aspects of the present invention include a pharmaceutical combination comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or anyone of the aldose reductase inhibitors identified above, or any one of the AII antagonists identified above. Accordingly, further independent aspects of the present invention include the following:
  • the ‘pharmaceutical combination’ may be achieved by dosing each component drug of the combination to the patient separately in individual dosage forms administered together or sequentially. Alternatively the ‘pharmaceutical combination’ may be together in the same unit dosage form.
  • composition comprising a pharmaceutical combination as described herein above together with a pharmaceutically acceptable carrier and/or diluent.
  • Independent aspects of the present invention include a pharmaceutical composition comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or any one of the aldose reductase inhibitors identified above, or any one of the AII antagonists identified above together with a pharmaceutically acceptable carrier and/or diluent. Accordingly, further independent aspects of the present invention include the following:
  • a preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an ACE inhibitor (including any one of the ACE inhibitors specifically named above, in particular lisinopril), together with a pharmaceutically acceptable carrier and/or diluent.
  • a preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an aldose reductase inhibitor (including any one specifically named above), together with a pharmaceutically acceptable carrier and/or diluent.
  • a preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an AII antagonist (including any one specifically named above and preferably candesartan), together with a pharmaceutically acceptable carrier and/or diluent.
  • compositions of the present invention may be administered in a standard manner for example by oral or parenteral administration, using conventional systemic dosage forms, such as a tablets, capsules, pills, powders, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions.
  • dosage forms will include the necessary carrier material, excipient, lubricant, buffer, bulking agent, antioxidant, dispersant or the like.
  • compositions for oral administration are preferred.
  • the dose of a statin drug, an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor which can be administered in accordance with the present invention depends on several factors, for example the age, weight and the severity of the condition under treatment, as well as the route of administration, dosage form and regimen and the desired result, and additionally the potency of the statin drug, aldose reductase inhibitor, AII antagonist and ACE inhibitor employed in the composition. In addition, account should be taken of the recommended maximum daily dosages for the ACE inhibitors.
  • Prolonged administration of an ACE inhibitor at a therapeutically effective dose may be deleterious or give rise to side effects in certain patients, for example it may lead to significant deterioration of renal function, induce hyperkalemia, neutropenia, angioneurotic oedema, rash or diarrhoea or give rise to a dry cough.
  • Administration of an ARI may also give rise to deleterious effects or side effects at the dose required to inhibit the enzyme aldose reductase sufficiently to produce a significant beneficial therapeutic effect.
  • the present invention lessens the problems associated with administration of an ARI or an ACE inhibitor alone and/or provides a means for obtaining a therapeutic effect which is significantly greater than that otherwise obtainable with the single agents when administered alone.
  • diabetic neuropathy involve a complex mechanism or number of mechanisms, which initiate a cascade of biochemical alterations that in turn lead to structural changes. These may result in a diverse patient population.
  • the present invention therefore provides the additional advantage that it allows tailoring of treatment to the needs of a particular patient population.
  • statin preferably atorvastatin or the AGENT
  • ACE inhibitor preferably lisinopril
  • statin preferably atorvastatin or the AGENT
  • AII antagonist preferably candesartan
  • a unit dosage formulation such as a tablet or capsule will usually contain, for example, from 1 mg to 100 mg of the statin drug, or/and from 0.1 mg to 500 mg of an aldose reductase inhibitor, or/and from 0.1 mg to 500 mg of an ACE inhibitor.
  • a unit dose formulation will contain 5 to 80 mg of the statin drug, or/and 0.1 to 100 mg of an aldose reductase inhibitor, or/and 0.1 mg to 100 mg of an AII antagonist or/and 0.1 to 100 mg of an ACE inhibitor.
  • the present invention covers the pharmaceutical combination of (or product containing) the statin and an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor for simultaneous, separate or sequential use in the treatment of diabetic neuropathy.
  • the AGENT drug and the aldose reductase inhibitor or AII antagonist or ACE inhibitor is presented in admixture in one pharmaceutical dosage form.
  • the present invention covers the administration of separate unit dosages of the AGENT and aldose reductase inhibitor or AII antagonist or ACE inhibitor in order to achieve the desired therapeutic effect. Such separate unit dosages may be administered concurrently or sequentially as determined by the clinician.
  • the present invention also covers an agent for the treatment of diabetic neuropathy comprising a pharmaceutically acceptable carrier and/or diluent and, as active agents, a statin drug, preferably the AGENT or atorvastatin, and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in quantities producing a synergistic therapeutic effect.
  • a statin drug preferably the AGENT or atorvastatin
  • an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in quantities producing a synergistic therapeutic effect.
  • a combination of pharmaceutical compositions for combination therapy of diabetic neuropathy consisting of a pharmaceutical composition comprising the statin drug and a pharmaceutical composition comprising an aldose reductase inhibitor or a pharmaceutical composition comprising an AII antagonist or a pharmaceutical composition comprising an ACE inhibitor.
  • a further aspect of the present invention comprises the use of a statin drug and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in the preparation of a pharmaceutical composition for use in the treatment of diabetic neuropathy.
  • a further aspect of the present invention is a method for treating diabetic neuropathy wherein a therapeutically effective amount of a statin drug in combination with an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor is administered systemically, such as orally or parenterally.
  • a therapeutically effective amount of a statin drug in combination with an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor is administered systemically, such as orally or parenterally.
  • the ACE inhibitor or AII antagonist will preferably be administered in amounts below that required to cause a reduction in blood pressure.
  • the ACE inhibitor or AII antagonist will preferably be used in amounts usually employed to treat hypertension.
  • the effect of a pharmaceutical composition of the present invention may be examined by using one or more of the published models of diabetic neuropathy well known in the art.
  • the pharmaceutical compositions of the present invention are particularly useful for the prevention of, reducing the development of, or reversal of, deficits in nerve function found in diabetic patients, and therefore particularly useful in the treatment of diabetic neuropathy. This may be demonstrated, for example, by measuring markers such as nerve conduction velocity, nerve blood flow, nerve evoked potential amplitude, quantitative sensory testing, autonomic function testing and morphometric changes.
  • markers such as nerve conduction velocity, nerve blood flow, nerve evoked potential amplitude, quantitative sensory testing, autonomic function testing and morphometric changes.
  • a further aspect of the present invention is a method of treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
  • a further aspect of the present invention is a method of reversing impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
  • Dosages of the AGENT may be administered according to the cholesterol lowering effect desired from a range of 5-80 mg per day in any number of unit dosages.
  • Suitable dosages of the statins, ACE inhibitors, aldose reductase inhibitors or AII antagonists mentioned herein are those which are available commercially, and which may be further reduced as suggested herein, or as advised in such publications as Monthly Index of Medical Specialities (P.O. BOX 43, Ruislip, Middlesex, UK).
  • compositions of an aldose reductase inhibitor include the following:
  • Suitable pharmaceutical compositions of an ACE inhibitor include the following:
  • ACE Inhibitor 100 Corn starch 50 Gelatin 7.5 Microcrystalline cellulose 25 Magnesium stearate 2.5 Tablet 2 ACE inhibitor 20 Pregelatinised starch 82 Microcrystalline cellulose 82 Magnesium stearate 1
  • Capsules containing 1, 2.5 or 10 mg of the Agent may be obtained similarly using more or less lactose as appropriate, to achieve a fill weight of 105 mg.
  • compositions containing the AGENT and an ACE inhibitor in a single dosage form include the following:
  • a patient requiring treatment for diabetic neuropathy is treated with the AGENT (10 mg) and lisinopril (10 mg). Lisinopril is administered twice daily and the AGENT is administered once daily.
  • mice Male Sprague-Dawley rats, 19 weeks old at the start of the study, were divided into non-diabetic animals (normal control group) and animals rendered diabetic by intraperitoneal administration of streptozotocin, (40-45 mg/kg, freshly dissolved in sterile saline). Diabetes was verified 24 hours later by estimating hyperglycaemia and glucosuria (Visidex II and Diastix; Ames, Slough, UK). Diabetic rats were tested weekly and weighed daily. Animals were rejected if the plasma glucose concentration was ⁇ 20 mM of if body weight consistently increased over 3 days.
  • rats were anaesthetised with thiobutabarbitone by intraperitoneal injection (50-100 mg/kg).
  • the trachea was cannulated for artificial ventilation and a carotid cannula was used to monitor mean systemic blood pressure.
  • Sciatic blood flow was measured by hydrogen clearance microelectrode polarography (as described by Cameron et al., Diabetologia, 1994, vol. 37, pages 651-663).
  • the nerve was exposed between the sciatic notch and the knee and the skin around the incision was sutured to a metal ring to form a pool that was filled with paraffin oil that was maintained at 35-37° C. by radiant heat.
  • a glass-insulated platinum micro-electrode was inserted into the middle portion of the sciatic nerve and polarised at 250 mV with respect to a subcutaneous reference microelectrode. 10% Hydrogen was added to the inspired gas, the proportions of nitrogen and oxygen being adjusted to 70% and 20% respectively.
  • Non-diabetical control 64.04 ⁇ 0.46 (10) 8 week diabetic + vehicle 50.35 ⁇ 0.93 (6) Atorvastatin 9Diabetic + 2 weeks of dosing at 20 mg/kg 61.53 ⁇ 0.76 (6) Diabetic + 2 weeks of dosing at 50 mg/kg 63.59 ⁇ 0.69 (6) The AGENT Diabetic + 2 weeks of dosing at 20 mg/kg 63.34 ⁇ 0.61 (8) Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20 mg/kg - ED 50 2.3 mg/kg
  • Non-diabetic control 61.09 m/s ⁇ 0.67 (10) 8 week diabetic + vehicle 52.77 m/s ⁇ 0.79 (6) Atorvastatin Diabetic + 2 weeks of dosing at 20 mg/kg 59.77 m/s ⁇ 0.93 (6) Diabetic + 2 weeks of dosing at 50 mg/kg 60.72 m/s ⁇ 0.94 (6) The AGENT Diabetic + 2 weeks of dosing at 20 mg/kg 60.57 m/s ⁇ 0.83 (8) Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20 mg/kg - ED 50 0.9 mg/kg
  • Non-diabetic control 17.89 ml/min/100 g (of nerve tissue) ⁇ 0.65 (10) 8 week diabetic + vehicle 8.82 ml/min/100 g ⁇ 0.56 (10) Atorvastatin Diabetic + 2 weeks of dosing at 50 mg/kg 16.96 ⁇ 1.39 ml/min/100 g (6) The AGENT Diabetic + 2 weeks of dosing at 20 mg/kg 16.19 ⁇ 0.51 ml/min/100 g (8)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.

Description

  • The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
  • 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG Co A) reductase inhibitors effectively inhibit cholesterol synthesis in the liver through stimulation of the low density lipoprotein (LDL) receptors. These drugs are currently pre-eminent in the treatment of all hypercholesterolaemia, except the relatively rarely occurring homozygous familial hypercholesterolaemia. Therapy with HMG Co A-reductase inhibitors may result in regression of atherosclerotic vascular lesions and several HMG Co A-reductase inhibitors have proven to reduce mortality. Various HMG Co A-reductase inhibitors are marketed, and are collectively referred to as ‘statins’.
  • We have discovered that statin drugs, in particular (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the AGENT), the calcium salt of which is shown in FIG. 1 below, and atorvastatin produce an improvement in the nerve conduction velocity (NCV) and nerve blood flow in an animal model of diabetic neuropathy. Therefore, statin drugs may be used to improve diabetic neuropathy, whether in type I or type II diabetes.
  • Therefore we present as a first feature of the invention a method for treating neuropathy in a patient suffering from diabetes comprising administering to the patient a statin drug.
  • As a preferred feature of the invention we present a method for improving nerve conduction velocity and/or nerve blood flow in a patient suffering diabetic neuropathy comprising administering to the patient a statin drug.
  • Further features of the invention include use of a statin drug in the preparation of a medicament for use in the treatment of any of the conditions mentioned above.
  • Examples of statin drugs include, for example, pravastatin (PRAVACHOL™, lovastatin (MEVACOR™), simvastatin (ZOCOR™), cerivastatin (LIPOBAY™), fluvastatin (LESCOL™), atorvastatin (LIPITOR™) and the AGENT, the structures of which are shown in FIG. 1. Preferably the statin drug is atorvastatin or the AGENT. Preferably the AGENT is used at a dose of 5 to 80 mg per day.
  • The AGENT is disclosed in European Patent Application, Publication No. 0521471, and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444 as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase). Preferably the calcium salt is used as illustrated in FIG. 1.
  • Atorvastatin is disclosed in U.S. Pat. No. 5,273,995; lovastatin is disclosed in U.S. Pat. No. 4,231,938; simvastatin is disclosed U.S. Pat. No. 4,450,171 and U.S. Pat. No. 4,346,227; pravastatin is disclosed in U.S. Pat. No. 4,346,227; fluvastatin is disclosed in U.S. Pat. No. 4,739,073; cerivastatin is disclosed in U.S. Pat. No. 5,177,080 and U.S. Pat. No. 5,006,530.
  • Other compounds which have inhibitory activity against HMG-CoA reductase can be readily identified by using assays well known in the art. Examples of such assays are disclosed in U.S. Pat. No. 4,231,938 at column 6 and WO84/02131 at pages 30-33.
  • It will be appreciated that the statin drug may be administered in accordance with the invention in combination with other drugs used for treating diabetes or the complications of diabetes, such as neuropathy, nephropathy, retinopathy and cataracts. Examples of such treatments include insulin sensitising agents, insulin and oral hypoglycaemics (these are divided into four classes of drug—sulfonylureas, biguanides, prandial glucose regulators and alpha-glucosidase inhibitors). Examples of insulin sensitising agents include, for example, troglitazone, rosiglitazone, pioglitazone, MCC-555, (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid and 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid. Examples of sulfonylureas are glimepiride, glibenclamide, gliclazide, glipizide, gliquidone and tolazamide. An example of a biguanide is metformin. An example of an alpha-glucosidase inhibitor is acarbose. An example of a prandial glucose regulator is repaglinide.
  • Other treatments are known also to improve NCV in diabetic neuropathy and as such these represent preferred combinations of the invention. Examples of such treatments include aldose reductase inhibitors, ACE inhibitors and AII antagonists.
  • The use of aldose reductase inhibitors or ACE inhibitors in improving NCV and treating diabetic neuropathy is disclosed in PCT/GB98/01959. The use of AII antagonists in improving NCV and treating diabetic neuropathy is disclosed in WO93/20816.
  • Suitable aldose reductase inhibitors include, for example, epalrestat, tolrestat, ponolrestat, zopolrestat, AD-5467, SNK-860, ADN-138, AS-3201, zenarestat, sorbinil, methosorbinil, imirestat and minalrestat (WAY-121509).
  • Suitable ACE inhibitors include, for example, benazepril, benazeprilat, captopril, delapril, fentiapril, fosinopril, imidopril, libenzapril, moexipril, pentopril, perindopril, pivopril, quinapril, quinaprilat, ramipril, spirapril, spiraprilat, trandolapril, zofenopril, ceronapril, enalapril, indolapril, lisinopril, alacepril, and cilazapril. A preferred ACE inhibitor includes, for example, lisinopril, or a pharmaceutically acceptable salt thereof.
  • Suitable AII antagonists include, for example, losartan, irbesartan, valsartan and candesartan. A preferred AII antagonist is candesartan.
  • Independent aspects of the present invention include a pharmaceutical combination comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or anyone of the aldose reductase inhibitors identified above, or any one of the AII antagonists identified above. Accordingly, further independent aspects of the present invention include the following:
    • (1) A pharmaceutical combination comprising the AGENT and lisinopril;
    • (2) A pharmaceutical combination comprising atorvastatin and lisinopril;
    • (3) A pharmaceutical combination comprising fluvastatin and lisinopril;
    • (4) A pharmaceutical combination comprising pravastatin and lisinopril;
    • (5) A pharmaceutical combination comprising cerivastatin and lisinopril;
    • (6) A pharmaceutical combination comprising the AGENT and candesartan;
    • (7) A pharmaceutical combination comprising the AGENT, or atorvastatin, and (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid
  • The ‘pharmaceutical combination’ may be achieved by dosing each component drug of the combination to the patient separately in individual dosage forms administered together or sequentially. Alternatively the ‘pharmaceutical combination’ may be together in the same unit dosage form.
  • Therefore, as a further aspect of the invention we represent a pharmaceutical composition comprising a pharmaceutical combination as described herein above together with a pharmaceutically acceptable carrier and/or diluent.
  • Independent aspects of the present invention include a pharmaceutical composition comprising any one of the statin drugs identified above, preferably the AGENT or atorvastatin, and any one of the named ACE inhibitors identified above, or any one of the aldose reductase inhibitors identified above, or any one of the AII antagonists identified above together with a pharmaceutically acceptable carrier and/or diluent. Accordingly, further independent aspects of the present invention include the following:
    • (1) A pharmaceutical composition comprising the AGENT and lisinopril;
    • (2) A pharmaceutical composition comprising atorvastatin and lisinopril;
    • (3) A pharmaceutical composition comprising fluvastatin and lisinopril;
    • (4) A pharmaceutical composition comprising pravastatin and lisinopril;
    • (5) A pharmaceutical composition comprising cerivastatin and lisinopril;
    • (6) A pharmaceutical composition comprising AGENT and candesartan; and
    • (7) A pharmaceutical composition comprising the AGENT, or atorvastatin, and (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid; and
      • together with a pharmaceutically acceptable carrier and/or diluent.
  • A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an ACE inhibitor (including any one of the ACE inhibitors specifically named above, in particular lisinopril), together with a pharmaceutically acceptable carrier and/or diluent.
  • A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an aldose reductase inhibitor (including any one specifically named above), together with a pharmaceutically acceptable carrier and/or diluent.
  • A preferred pharmaceutical composition of the invention comprises the AGENT or atorvastatin and an AII antagonist (including any one specifically named above and preferably candesartan), together with a pharmaceutically acceptable carrier and/or diluent.
  • The pharmaceutical compositions of the present invention may be administered in a standard manner for example by oral or parenteral administration, using conventional systemic dosage forms, such as a tablets, capsules, pills, powders, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions. These dosage forms will include the necessary carrier material, excipient, lubricant, buffer, bulking agent, antioxidant, dispersant or the like. In particular, compositions for oral administration are preferred.
  • The dose of a statin drug, an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor which can be administered in accordance with the present invention depends on several factors, for example the age, weight and the severity of the condition under treatment, as well as the route of administration, dosage form and regimen and the desired result, and additionally the potency of the statin drug, aldose reductase inhibitor, AII antagonist and ACE inhibitor employed in the composition. In addition, account should be taken of the recommended maximum daily dosages for the ACE inhibitors.
  • Prolonged administration of an ACE inhibitor at a therapeutically effective dose may be deleterious or give rise to side effects in certain patients, for example it may lead to significant deterioration of renal function, induce hyperkalemia, neutropenia, angioneurotic oedema, rash or diarrhoea or give rise to a dry cough. Administration of an ARI may also give rise to deleterious effects or side effects at the dose required to inhibit the enzyme aldose reductase sufficiently to produce a significant beneficial therapeutic effect. The present invention lessens the problems associated with administration of an ARI or an ACE inhibitor alone and/or provides a means for obtaining a therapeutic effect which is significantly greater than that otherwise obtainable with the single agents when administered alone. Furthermore, diabetic neuropathy involve a complex mechanism or number of mechanisms, which initiate a cascade of biochemical alterations that in turn lead to structural changes. These may result in a diverse patient population. The present invention therefore provides the additional advantage that it allows tailoring of treatment to the needs of a particular patient population.
  • The combination of a statin, preferably atorvastatin or the AGENT, with and ACE inhibitor, preferably lisinopril, is either additive or synergistic in effect in the treatment of neuropathy, in particular NCV or nerve blood flow, in diabetic patients.
  • The combination of a statin, preferably atorvastatin or the AGENT, with and AII antagonist, preferably candesartan, is either additive or synergistic in effect in the treatment of neuropathy, in particular NCV or nerve blood flow, in diabetic patients.
  • A unit dosage formulation such as a tablet or capsule will usually contain, for example, from 1 mg to 100 mg of the statin drug, or/and from 0.1 mg to 500 mg of an aldose reductase inhibitor, or/and from 0.1 mg to 500 mg of an ACE inhibitor. Preferably a unit dose formulation will contain 5 to 80 mg of the statin drug, or/and 0.1 to 100 mg of an aldose reductase inhibitor, or/and 0.1 mg to 100 mg of an AII antagonist or/and 0.1 to 100 mg of an ACE inhibitor.
  • The present invention covers the pharmaceutical combination of (or product containing) the statin and an aldose reductase inhibitor, an AII antagonist or an ACE inhibitor for simultaneous, separate or sequential use in the treatment of diabetic neuropathy. In one aspect of the present invention, the AGENT drug and the aldose reductase inhibitor or AII antagonist or ACE inhibitor is presented in admixture in one pharmaceutical dosage form. In another aspect, the present invention covers the administration of separate unit dosages of the AGENT and aldose reductase inhibitor or AII antagonist or ACE inhibitor in order to achieve the desired therapeutic effect. Such separate unit dosages may be administered concurrently or sequentially as determined by the clinician. The present invention also covers an agent for the treatment of diabetic neuropathy comprising a pharmaceutically acceptable carrier and/or diluent and, as active agents, a statin drug, preferably the AGENT or atorvastatin, and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in quantities producing a synergistic therapeutic effect.
  • In another aspect of the invention there is provided a combination of pharmaceutical compositions for combination therapy of diabetic neuropathy, the combination consisting of a pharmaceutical composition comprising the statin drug and a pharmaceutical composition comprising an aldose reductase inhibitor or a pharmaceutical composition comprising an AII antagonist or a pharmaceutical composition comprising an ACE inhibitor.
  • A further aspect of the present invention comprises the use of a statin drug and an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor in the preparation of a pharmaceutical composition for use in the treatment of diabetic neuropathy.
  • A further aspect of the present invention is a method for treating diabetic neuropathy wherein a therapeutically effective amount of a statin drug in combination with an aldose reductase inhibitor or an AII antagonist or an ACE inhibitor is administered systemically, such as orally or parenterally. Where the patient to be treated is normotensive, the ACE inhibitor or AII antagonist will preferably be administered in amounts below that required to cause a reduction in blood pressure. Where the patient to be treated is hypertensive, the ACE inhibitor or AII antagonist will preferably be used in amounts usually employed to treat hypertension.
  • The effect of a pharmaceutical composition of the present invention may be examined by using one or more of the published models of diabetic neuropathy well known in the art. The pharmaceutical compositions of the present invention are particularly useful for the prevention of, reducing the development of, or reversal of, deficits in nerve function found in diabetic patients, and therefore particularly useful in the treatment of diabetic neuropathy. This may be demonstrated, for example, by measuring markers such as nerve conduction velocity, nerve blood flow, nerve evoked potential amplitude, quantitative sensory testing, autonomic function testing and morphometric changes. Experimentally, studies analogous to those described in Diabetologia, 1992, Vol. 35, pages 12-18 and 1994, Vol. 37, pages 651-663 may be carried out.
  • A further aspect of the present invention is a method of treating or preventing the development of disease conditions associated with impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
  • A further aspect of the present invention is a method of reversing impaired neuronal conduction velocity in a warm-blooded animal (including a human being) requiring such treatment comprising administering to said animal a therapeutically effective amount of a pharmaceutical combination or composition as described above.
  • Dosages of the AGENT may be administered according to the cholesterol lowering effect desired from a range of 5-80 mg per day in any number of unit dosages.
  • Suitable dosages of the statins, ACE inhibitors, aldose reductase inhibitors or AII antagonists mentioned herein are those which are available commercially, and which may be further reduced as suggested herein, or as advised in such publications as Monthly Index of Medical Specialities (P.O. BOX 43, Ruislip, Middlesex, UK).
  • The following non-limiting Examples serve to illustrate the present invention.
    • EXAMPLE 1
  • Suitable pharmaceutical compositions of an aldose reductase inhibitor (ARI) include the following:
  • mg/tablet
    Tablet 1
    ARI 100
    Lactose Ph. Eur. 182.75
    Croscarmellose sodium 12.0
    Maize starch paste (5% w/v paste) 2.25
    Magnesium stearate 3.0
    Tablet 2
    ARI 50
    Lactose Ph. Eur. 223.75
    Croscarmellose sodium 6.0
    Maize starch 15.0
    Polyvinylpyrrolidone (5% w/v paste) 2.25
    Magnesium stearate 3.0
    Tablet 3
    ARI 1.0
    Lactose Ph. Eur. 93.25
    Croscarmellose sodium 4.0
    Maize starch paste (5% w/v paste) 0.75
    Magnesium stearate 1.0
    Capsule 1
    ARI 10
    Lactose Ph. Eur. 488.5
    Magnesium stearate 1.5
    • EXAMPLE 2
  • Suitable pharmaceutical compositions of an ACE inhibitor include the following:
  •
    Tablet 1
    ACE Inhibitor 100
    Corn starch 50
    Gelatin 7.5
    Microcrystalline cellulose 25
    Magnesium stearate 2.5
    Tablet 2
    ACE inhibitor 20
    Pregelatinised starch 82
    Microcrystalline cellulose 82
    Magnesium stearate 1
    • EXAMPLE 3
  • Capsule mg
    The AGENT 5.0
    Lactose 42.5
    Corn starch 20.0
    Microcrystalline cellulose 32.0
    Pregelatinised starch 3.3
    Hydrotalcite 1.1
    Magnesium stearate 1.1
  • Capsules containing 1, 2.5 or 10 mg of the Agent may be obtained similarly using more or less lactose as appropriate, to achieve a fill weight of 105 mg.
    • EXAMPLE 4
  • Suitable pharmaceutical compositions containing the AGENT and an ACE inhibitor in a single dosage form include the following:
  • Capsule mg
    The AGENT 5.0
    Lisinopril 10.0
    Lactose 42.5
    Corn starch 20.0
    Microcrystalline cellulose 32.0
    Pregelatinised starch 3.3
    Hydrotalcite 1.1
    Magnesium stearate 1.1
    • EXAMPLE 5
  • A patient requiring treatment for diabetic neuropathy is treated with the AGENT (10 mg) and lisinopril (10 mg). Lisinopril is administered twice daily and the AGENT is administered once daily.
    • EXAMPLE 6
  • Male Sprague-Dawley rats, 19 weeks old at the start of the study, were divided into non-diabetic animals (normal control group) and animals rendered diabetic by intraperitoneal administration of streptozotocin, (40-45 mg/kg, freshly dissolved in sterile saline). Diabetes was verified 24 hours later by estimating hyperglycaemia and glucosuria (Visidex II and Diastix; Ames, Slough, UK). Diabetic rats were tested weekly and weighed daily. Animals were rejected if the plasma glucose concentration was <20 mM of if body weight consistently increased over 3 days. Samples were taken from the tail vein or carotid artery after final experiments for plasma glucose determination (GOD-Perid method; Boehringer Mannheim, Mannheim, Germany). After 6 weeks of untreated diabetes, groups of rats were treated for a further 2 weeks with the AGENT, dissolved in the drinking water.
  • At the end of the treatment period, rats were anaesthetised with thiobutabarbitone by intraperitoneal injection (50-100 mg/kg). The trachea was cannulated for artificial ventilation and a carotid cannula was used to monitor mean systemic blood pressure.
  • Motor nerve conduction velocity was measured (as previously described by Cameron et al, Diabetologia, 1993, Vol. 36, pages 299-304) between sciatic notch and knee in the nerve branch to tibialis anterior muscle, which is representative of the whole sciatic nerve in terms of susceptibility to diabetes and treatment effects.
  • Sensory conduction velocity in saphenous nerve was measured between the groin and ankle (as previously described by Cameron et al. Quarterly Journal of Experimental Physiology, 1989, vol. 74, pages 917-926).
  • Sciatic blood flow was measured by hydrogen clearance microelectrode polarography (as described by Cameron et al., Diabetologia, 1994, vol. 37, pages 651-663). The nerve was exposed between the sciatic notch and the knee and the skin around the incision was sutured to a metal ring to form a pool that was filled with paraffin oil that was maintained at 35-37° C. by radiant heat. A glass-insulated platinum micro-electrode was inserted into the middle portion of the sciatic nerve and polarised at 250 mV with respect to a subcutaneous reference microelectrode. 10% Hydrogen was added to the inspired gas, the proportions of nitrogen and oxygen being adjusted to 70% and 20% respectively. When the hydrogen current recorded by the electrode had stabilised, indicating equilibrium with arterial blood, the hydrogen supply was shut off and nitrogen supply was increased appropriately. The hydrogen clearance curve was recorded until a baseline, defined as no systematic decline in electrode current over 5 minutes. To estimate blood flow, clearance curves were digitised and exponential curves were fitted to the data by computer using non-linear regression. The best fitting exponent gave a measure of nerve blood flow.
    • Data
  • All data expressed as group mean ±SEM (number of rats used in brackets)
    • Sciatic Nerve Motor Conduction Velocity
  • Control Values
    Non-diabetical control  64.04 ± 0.46 (10)
    8 week diabetic + vehicle 50.35 ± 0.93 (6)
    Atorvastatin
    9Diabetic + 2 weeks of dosing at 20 mg/kg 61.53 ± 0.76 (6)
    Diabetic + 2 weeks of dosing at 50 mg/kg 63.59 ± 0.69 (6)
    The AGENT
    Diabetic + 2 weeks of dosing at 20 mg/kg 63.34 ± 0.61 (8)
    Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20 mg/kg - ED50 = 2.3 mg/kg
    • Saphenous Nerve Sensory Conduction Velocity
  • Control Values
    Non-diabetic control 61.09 m/s ± 0.67 (10)
    8 week diabetic + vehicle 52.77 m/s ± 0.79 (6)
    Atorvastatin
    Diabetic + 2 weeks of dosing at 20 mg/kg 59.77 m/s ± 0.93 (6)
    Diabetic + 2 weeks of dosing at 50 mg/kg 60.72 m/s ± 0.94 (6)
    The AGENT
    Diabetic + 2 weeks of dosing at 20 mg/kg 60.57 m/s ± 0.83 (8)
    Dose response determination 5 groups of 8 rats - dose ranged from 0.3-20 mg/kg - ED50 = 0.9 mg/kg
    • Sciatic Nerve Blood Flow
  • Control Values
    Non-diabetic control 17.89 ml/min/100 g (of nerve
    tissue) ± 0.65 (10)
    8 week diabetic + vehicle 8.82 ml/min/100 g ± 0.56 (10)
    Atorvastatin
    Diabetic + 2 weeks of dosing at 50 mg/kg 16.96 ± 1.39 ml/min/100 g (6)
    The AGENT
    Diabetic + 2 weeks of dosing at 20 mg/kg 16.19 ± 0.51 ml/min/100 g (8)
  • Figure US20090186908A1-20090723-C00001
    Figure US20090186908A1-20090723-C00002

Claims (7)

1-17. (canceled)
18. A pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof and candesartan.
19-21. (canceled)
22. A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, candesartan and a pharmaceutically acceptable diluent or carrier.
23. A unit dosage formulation comprising a pharmaceutical combination according to claim 18.
24. A unit dosage formulation comprising a pharmaceutical composition according to claim 22.
25. The unit dosage formulation of claim 18 or claim 22 wherein the (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5 S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof is present in said formulation in an amount of from 5 to 80 mg, and the candesartan is present in an amount of from 0.1 to 100 mg.
US12/222,534 1999-02-06 2008-08-11 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy Abandoned US20090186908A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/222,534 US20090186908A1 (en) 1999-02-06 2008-08-11 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US13/048,377 US20120041010A1 (en) 1999-02-06 2011-03-15 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GB9902594.2 1999-02-06
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GB9902591.8 1999-02-06
US09/889,409 US6894058B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US10/935,747 US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US12/222,534 US20090186908A1 (en) 1999-02-06 2008-08-11 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/935,747 Continuation US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US10/935,747 Division US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/048,377 Division US20120041010A1 (en) 1999-02-06 2011-03-15 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan

Publications (1)

Publication Number Publication Date
US20090186908A1 true US20090186908A1 (en) 2009-07-23

Family

ID=26315085

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/889,409 Expired - Lifetime US6894058B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US10/935,747 Abandoned US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US12/222,534 Abandoned US20090186908A1 (en) 1999-02-06 2008-08-11 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US13/048,377 Abandoned US20120041010A1 (en) 1999-02-06 2011-03-15 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/889,409 Expired - Lifetime US6894058B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US10/935,747 Abandoned US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/048,377 Abandoned US20120041010A1 (en) 1999-02-06 2011-03-15 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan

Country Status (33)

Country Link
US (4) US6894058B1 (en)
EP (2) EP1150678B1 (en)
JP (3) JP2002536332A (en)
KR (1) KR100699757B1 (en)
CN (1) CN1196488C (en)
AR (1) AR025512A1 (en)
AT (2) ATE485823T1 (en)
AU (1) AU763970B2 (en)
BR (1) BR0007996A (en)
CA (1) CA2368186C (en)
CY (2) CY1106879T1 (en)
CZ (2) CZ302881B6 (en)
DE (2) DE60045168D1 (en)
DK (2) DK1150678T3 (en)
EE (2) EE05556B1 (en)
ES (2) ES2352803T3 (en)
GB (1) GB0001662D0 (en)
HU (1) HU227642B1 (en)
IL (3) IL144730A0 (en)
IS (2) IS2793B (en)
MX (1) MXPA01007821A (en)
MY (1) MY138289A (en)
NO (1) NO330400B1 (en)
NZ (3) NZ513061A (en)
PL (1) PL198098B1 (en)
PT (2) PT1897546E (en)
RU (1) RU2239456C2 (en)
SI (2) SI1897546T1 (en)
SK (2) SK287792B6 (en)
TR (1) TR200102229T2 (en)
TW (1) TWI230067B (en)
WO (1) WO2000045818A1 (en)
ZA (1) ZA200105885B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275989A1 (en) * 2003-09-26 2007-11-29 Mehta Jay L Therapeutic Treatment

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
CA2382549C (en) 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001058491A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Drug comprising combination
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (en) * 2000-05-23 2001-11-29 Bayer Ag Combination of cerivastatin with ACE inhibitors and their use in medicinal products
PE20020617A1 (en) * 2000-08-22 2002-08-05 Novartis Ag COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
AR030379A1 (en) * 2000-08-22 2003-08-20 Novartis Ag COMBINATIONS
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
ATE401886T1 (en) * 2000-10-12 2008-08-15 Nissan Chemical Ind Ltd ACTIVE INGREDIENTS FOR PREVENTING AND TREATING COMPLICATIONS RELATED TO DIABETES
KR20040025874A (en) * 2000-10-18 2004-03-26 화이자 프로덕츠 인크. Combination of statins and sorbitol dehydrogenase inhibitors
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
AR039090A1 (en) * 2002-03-22 2005-02-09 Novartis Ag COMBINATION OF ORGANIC COMPOUNDS
JP4395633B2 (en) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 Method for differentiation and maturation of non-neuronal cells into neurons, the composition and the method for searching for the composition
DE10302452B4 (en) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituted acyl-phenyl-urea derivatives, processes for their preparation and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
US7772272B2 (en) 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
JP2005232151A (en) * 2003-04-28 2005-09-02 Iichiro Shimomura Sugar uptake ability-reinforcing agent
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
CA2529538C (en) * 2003-06-20 2011-04-26 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (en) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 Pharmaceutical Compositions for Diabetes Treatment
CN101632673B (en) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 Medicinal composition containing losartan, pioglitazone and rosuvastatin and new application thereof
WO2010028132A2 (en) * 2008-09-06 2010-03-11 Bionevia Pharmaceuticals, Inc. Novel choline cocrystal of epalrestat
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2779999A2 (en) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2015053589A1 (en) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 Composition for preventing or treating autoimmune disease, using complex of metformin and statin
KR101579656B1 (en) * 2013-12-12 2015-12-22 가천대학교 산학협력단 A pharmaceutical composition comprising pravastatin and valsartan
CN110747206B (en) * 2019-11-05 2021-11-23 昆明理工大学 3-hydroxy-3-methylglutaryl coenzyme A reductase gene RKHMGR and application thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US6103742A (en) * 1995-06-20 2000-08-15 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
US6337327B1 (en) * 1997-07-08 2002-01-08 Zeneca Limited Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
US6448280B1 (en) * 1992-04-13 2002-09-10 Zeneca Limited Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US20070275989A1 (en) * 2003-09-26 2007-11-29 Mehta Jay L Therapeutic Treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
AU675935B2 (en) 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
EP0754042A4 (en) * 1994-03-29 2004-06-23 Merck & Co Inc TREATMENT OF ATHEROSCLEROSIS
BR9708517A (en) 1996-04-05 1999-08-03 Takeda Chemical Industries Ltd Pharmaceutical composition process to prevent or treat angiotensin ii-mediated diseases in a mammal and use of a compound
GT199800126A (en) 1997-08-29 2000-01-29 COMBINATION THERAPY.
SE9801992D0 (en) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
US6448280B1 (en) * 1992-04-13 2002-09-10 Zeneca Limited Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US6121295A (en) * 1995-06-20 2000-09-19 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6169100B1 (en) * 1995-06-20 2001-01-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6384062B1 (en) * 1995-06-20 2002-05-07 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6103742A (en) * 1995-06-20 2000-08-15 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6337327B1 (en) * 1997-07-08 2002-01-08 Zeneca Limited Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
US20070275989A1 (en) * 2003-09-26 2007-11-29 Mehta Jay L Therapeutic Treatment

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275989A1 (en) * 2003-09-26 2007-11-29 Mehta Jay L Therapeutic Treatment
US20110046119A1 (en) * 2003-09-26 2011-02-24 Astrazeneca Ab Therapeutic treatment
US7932263B2 (en) 2003-09-26 2011-04-26 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
EE05621B1 (en) 2013-02-15
EE05556B1 (en) 2012-08-15
CN1196488C (en) 2005-04-13
BR0007996A (en) 2001-10-30
NZ536433A (en) 2006-08-31
IL208330A0 (en) 2010-12-30
NZ525419A (en) 2004-12-24
IL144730A (en) 2010-12-30
EE201200015A (en) 2012-10-15
SI1150678T1 (en) 2008-02-29
EP1150678A1 (en) 2001-11-07
JP2014065718A (en) 2014-04-17
US6894058B1 (en) 2005-05-17
NO330400B1 (en) 2011-04-04
EP1897546A1 (en) 2008-03-12
EP1150678B1 (en) 2007-07-18
NO20013812L (en) 2001-10-02
AU2304700A (en) 2000-08-25
PT1150678E (en) 2007-09-14
IS6016A (en) 2001-07-20
CN1338937A (en) 2002-03-06
ZA200105885B (en) 2002-10-17
SK286854B6 (en) 2009-06-05
PL350312A1 (en) 2002-12-02
TR200102229T2 (en) 2001-12-21
HK1118209A1 (en) 2009-02-06
SI1897546T1 (en) 2011-02-28
AU763970B2 (en) 2003-08-07
CA2368186A1 (en) 2000-08-10
ES2352803T3 (en) 2011-02-23
TWI230067B (en) 2005-04-01
KR100699757B1 (en) 2007-03-27
DE60035575D1 (en) 2007-08-30
EP1897546B1 (en) 2010-10-27
CZ20012806A3 (en) 2002-02-13
SK11102001A3 (en) 2002-05-09
GB0001662D0 (en) 2000-03-15
KR20010089635A (en) 2001-10-06
NO20013812D0 (en) 2001-08-03
NZ513061A (en) 2003-06-30
HUP0105138A3 (en) 2002-11-28
PT1897546E (en) 2010-12-15
DE60045168D1 (en) 2010-12-09
HK1041223A1 (en) 2002-07-05
US20120041010A1 (en) 2012-02-16
WO2000045818A1 (en) 2000-08-10
MY138289A (en) 2009-05-29
AR025512A1 (en) 2002-12-04
DK1897546T3 (en) 2011-01-17
JP2012051898A (en) 2012-03-15
CZ302893B6 (en) 2012-01-11
IL144730A0 (en) 2002-06-30
CY1110992T1 (en) 2015-06-11
DK1150678T3 (en) 2007-10-08
MXPA01007821A (en) 2004-08-19
ES2286995T3 (en) 2007-12-16
CY1106879T1 (en) 2012-05-23
ATE367162T1 (en) 2007-08-15
RU2239456C2 (en) 2004-11-10
CZ302881B6 (en) 2012-01-04
SK287792B6 (en) 2011-10-04
PL198098B1 (en) 2008-05-30
IS8978A (en) 2011-08-23
EE200100405A (en) 2002-10-15
HUP0105138A2 (en) 2002-04-29
US20050209128A1 (en) 2005-09-22
JP2002536332A (en) 2002-10-29
DE60035575T2 (en) 2008-04-03
CA2368186C (en) 2008-06-03
IS2793B (en) 2012-08-15
HU227642B1 (en) 2011-10-28
IS2820B (en) 2012-12-15
ATE485823T1 (en) 2010-11-15

Similar Documents

Publication Publication Date Title
US6894058B1 (en) Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US6337327B1 (en) Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
AU2007200367B2 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
AU2003255176B2 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
HK1041223B (en) Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
HK1118209B (en) Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
HK1028876B (en) Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION